ELTXElicio Therapeutics, Inc.
The schedule
- Thu15Oct
Expected fall clinical update detailing enrollment and interim safety/efficacy metrics for ELTX's lead immunotherapy assets, including ELI-002.
- Thu12Nov
Q3 results focusing on the balance sheet and cash runway, serving as a critical indicator of when ELTX will need to execute a dilutive financing round.
- Fri15Jan
Anticipated public offering or private placement (PIPE) to secure operational capital for ongoing Phase 2 clinical trials.
- Sun14Feb
Year-end financial update paired with a strategic outlook for clinical trial milestones across the 2027 calendar year.
- Mon10May
First-quarter update, functioning primarily as a table-setter for major summer medical conferences and anticipated clinical readouts.
- Fri4Jun
Expected presentation of updated efficacy and safety data for ELTX's oncology pipeline at the American Society of Clinical Oncology conference.
- Thu12Aug
Mid-year financial update detailing the strategic path forward following the summer clinical data readouts.
